# PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

> **NCT03093818** · NA · COMPLETED · sponsor: **J.J.Swen** · enrollment: 6950 (actual)

## Conditions studied

- Adverse Drug Reaction

## Interventions

- **OTHER:** Pharmacogenomic testing

## Key facts

- **NCT ID:** NCT03093818
- **Lead sponsor:** J.J.Swen
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-20
- **Primary completion:** 2020-09-30
- **Final completion:** 2021-05-01
- **Target enrollment:** 6950 (ACTUAL)
- **Last updated:** 2024-04-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03093818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03093818, "PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03093818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*